News

In a discussion with Managed Healthcare Executive, Jonathan I. Silverberg, M.D., Ph.D., M.P.H., an Associate Professor of Dermatology at The George Washington University School of Medicine and Health Sciences, discussed the concept of "atopic march."

There was no mention in President Joseph Biden's Statue of the Union Address about PBM reform, which has garnered a lot of interest from patient advocates and Congress over the last year.

The annual meeting will run through Tuesday.

John Barbieri, assistant professor at Harvard Medical School, is looking forward to the upcoming 2024 American Academy of Dermatology meeting, which runs from March 8-12 in San Diego. Barbieri is particularly showing interest in late-breaking abstracts and trial data and hoping to see cutting-edge information from pivotal clinical trials.

It was found in a recent study that the updated Moderna, Pfizer-BioNTech and Novavax COVID-19 vaccines, when combined with antiviral treatments like nirmatrelvir and molnupiravir, can significantly decrease the chances of hospitalization and death from current COVID-19 variants.

These researchers want to normalize menopause before treating symptoms with medicine.

In the third part of this video series, Susan Cantrell, CEO of AMCP, discusses the impact of drug prices on patient adherence with Managed Healthcare Executive.

Please pick the statement that most closely resembles your view of health insurance coverage of GLP-1s for weight loss.

There was only a total of 58 cases in 2023.

By embracing change, leveraging emerging trends and prioritizing patient-centered care, organizations and individuals can find opportunities for growth and innovation in the post-pandemic era.

Both Wyost and Jubbonti are interchangeable for the reference products and are approved for all of the same indications in osteoporosis and bone cancer.

Women experiencing high levels of poverty and those in impoverished rural regions are less likely to get screened for breast cancer, find a new review of studies that have assessed social determinants of health.

The FLOW trial was stopped early based on an interim analysis that found the study met the criteria for efficacy.

Hospitals and healthcare software developers are adjusting to a world in which blocking healthcare data will come with potentially stiff penalties under rules proposed by the Office of the National Coordinator for Health Information Technology (ONC).

Canadian health officials warn that maintaining a drug supply for Canadians is their priority. The staunch opposition of the U.S. pharmaceutical industry may also be an obstacle to imports from north of the border.

Advances in MS disease management have included the emergence of monoclonal antibodies as effective disease-modifying therapies (DMTs) for MS. FDA-approved treatments include Tysabri (natalizumab), Lemtrada (alemtuzumab), Ocrevus (ocrelizumab), and Kesimpta (ofatumumab).

ONC201 (dordaviprone) displayed “well tolerated and durable and clinically meaningful efficacy in Histone 3 (H3) K27M mutant-diffuse midline glioma DMG.”

CivicaScript, a generic medication manufacturer, is modeling itself as public utility. It launched its first product, abiraterone 250 mg tablets, late last year and is gearing up to make its own low-cost insulin.

A new study points to disparities for patients in respiratory failure, which can have dire consequences. The lead researchers talk about the implications.

FDA has expanded the indication for Biktarvy for those with resistant HIV, granted full approval to Rybrevant and approved Simlandi, the third interchangeable Humira biosimilar. The regulatory agency has also set action dates for sxatilimab in graft-versus-host disease, tislelizumab in stomach cancer and a second indication for Epkinly.

The company has confirmed that group representing itself as ALPHV/Blackcat, a ransomware-as-service criminal group known to cybersecurity experts, is behind the cyberattack on the pharmacy claims processor owned by UnitedHealth.

In this second part of a video series, AMCP CEO Susan Cantrell addressed the impact of high prescription drug prices on underserved communities, highlighting disparities in access caused by the pandemic's effects on minority populations. On the industry blame debate, she urged collaborative solutions, mentioning AMCP's engagement with diverse stakeholders to find comprehensive, patient-centric solutions and advocate for policy changes like the MVP Act to address rising costs and access challenges.

The results of this week’s poll about the recent Change Healthcare Cyberattack.

A total of 37 payers and providers have now signed on.

In this first part of a video series, Susan Cantrell, CEO of AMCP, discussed root causes of high drug prices, its impact on underserved communities and Medicare price negotiation, emphasizing AMCP's actions and the role of decreasing drug prices for equity.

Results of the evaluations will inform recommendations to payers and providers about whether and how to adopt these technologies.

One of the nation’s largest not for profit Medicare Advantage plans, SCAN Health Plan, is the first to use the feature.

Adolescent uptake levels of PrEP are low among adolescents ages 16-24 years old.